Clinical trials can be an exciting way to address a medical problem. Participation allows patients to receive medication that might otherwise not be available through any means, and the office visits and any blood tests or other diagnostic procedures associated with study are provided free of charge. In some cases there may also be a patient stipend for the time it takes out of your schedule and for transportation assistance. The research at NervePro consists of Phase III studies. This type of study involves medications or devices that have already been shown to be safe in preliminary Phase I and II studies and to have some degree of effectiveness in Phase II studies. Phase III studies test the medication on a larger number of participants with the expectation that the next step would be approval by the FDA if safety and efficacy are established.
Unlike many clinical trial centers, NervePro is an active neurology practice, and patients are under no pressure to participate in research if they chose not to. Those patients that have been involved in trials are allowed to stay in the practice as regular patients once their participation is completed if Dr. Cleeremans is a provider on their insurance plan.
The research division of NervePro Medical Corporation has successfully performed studies in Headache, Painful neuropathy, Seizures, Alzheimer’s and multi-infarct dementias, myofascial pain, fibromyalgia, low back pain, insomnia, multiple sclerosis, Parkinson’s Disease, TIAs, and strokes.
Dr. Cleeremans is the Principal Investigator, and is assisted by experienced research coordinator, Ana Martinez Clinical Coordinator. The direct line to inquire about clinical trials is (949) 753-1570. Feel free to e-mail at email@example.com.
Make a Research Appointment
Ongoing Clinical Trials:
Most approved medications have only a modest beneficial effect, it will be several years before new ones are available outside of a clinical trial, during which time those afflicted are steadily getting worse. At NervePro, we are participating in a phase III clinical trial for mild cognitive impairment and early to moderate Alzheimer’s dementia. The chemical blocks the production of amyloid and in earlier Phase I and II studies has been shown to be very safe. Biomarker’s show the medication works as targeted. It is too early to determine how effective this will be in stopping or reversing the clinical symptoms of this disease, but early reports are promising. This avenue of research has been recognized as promising by the FDA who has fast tracked several studies working in this area. Enrollment is starting in the beginning of January for this two year study and enrollment will likely continue for all of 2017.
We do not presently have an active migraine study. We have participated in two targeting the CGRP receptor in the past three years that have been promising and hopefully will be available in the market early in 2017.